VolitionRx Signs Global Supply Deal For Nu.Q Vet Cancer Test

(RTTNews) - VOLITIONRX LTD (VNRX), a life science firm company, said on Thursday that it has signed a global supply deal with an undisclosed party to distribute its Nu.Q Vet Cancer Test for cancer indications in animals.

Financial terms of the deal have not been disclosed.

Volition expects that the deal will support to screen those senior dogs aged over 7 years and breeds at risk of cancer from four years and above.

There are around 84 million pet dogs in the U.S. and just under half of the dogs will have at least one veterinary care visit per annum. Volition's Nu.Q Vet Cancer test detected 76 percent of systemic cancers, including lymphoma, hemangiosarcoma, and histiocytic sarcoma at 97 percent specificity versus control.